Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.50 |
| ▸ | SQLE | Q14534 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28182185 | 0.83 | KMT2A (0.50) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL5487439 | 0.82 | KMT2A (0.55) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL9136753 | 0.82 | KMT2A (0.64) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL17867409 | 0.81 | KMT2A (0.57) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL17265221 | 0.80 | ALOX15 (0.34) | ALOX15KDM4EALDH1A1 | |
| SCHEMBL17265277 | 0.80 | ALOX15 (0.34) | ALOX15KDM4EALDH1A1 | |
| SCHEMBL18897542 | 0.79 | KMT2A (0.67) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL127329 | 0.78 | KMT2A (0.58) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL536905 | 0.78 | KMT2A (0.58) | KMT2AFNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8850354 | 0.78 | KMT2A (0.64) | KMT2AFNTAFNTBMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | KMT2A 380/4885FNTA 2004/4885FNTB 243/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KMT2A 1011/4885FNTA 1939/4885FNTB 166/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | KMT2A 415/4885FNTA 1591/4885FNTB 130/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KMT2A 1011/4885FNTA 1939/4885FNTB 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.